The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•20 March 2026•

1 min read

Pharvaris Publishes Positive Phase 2 Data for Deucrictibant in The Lancet Haematology

Key Facts

1Pharvaris published Phase 2 data for deucrictibant in the prestigious journal The Lancet Haematology.

2The CHAPTER-1 and RAPIDe-1 studies demonstrated the efficacy and safety of the drug for prophylaxis and on-demand treatment of HAE attacks.

Pharvaris (Nasdaq: PHVS) announced the publication of results from two Phase 2 clinical trials for its lead drug candidate, deucrictibant, in the prestigious medical journal The Lancet Haematology. The CHAPTER-1 and RAPIDe-1 studies demonstrated the efficacy and safety of the drug for both the prophylaxis and on-demand treatment of Hereditary Angioedema (HAE) attacks. Deucrictibant is an oral small-molecule bradykinin B2 receptor antagonist designed to offer a more convenient and effective treatment option for patients. This peer-reviewed publication validates the drug's clinical potential, marking a significant scientific milestone for the company's development program. Following the announcement, investor confidence in the drug's path toward regulatory approval is expected to strengthen within the biotech sector. Pharvaris continues to advance its clinical pipeline as it seeks to address critical unmet needs in the global HAE market.